450 related articles for article (PubMed ID: 33289848)
21. Statins and erectile dysfunction: results of a case/non-case study using the French Pharmacovigilance System Database.
Do C; Huyghe E; Lapeyre-Mestre M; Montastruc JL; Bagheri H
Drug Saf; 2009; 32(7):591-7. PubMed ID: 19530745
[TBL] [Abstract][Full Text] [Related]
22. Association Between Antipsychotics and Osteoporosis Based on Real-World Data.
Yokoyama S; Wakamoto S; Tanaka Y; Nakagawa C; Hosomi K; Takada M
Ann Pharmacother; 2020 Oct; 54(10):988-995. PubMed ID: 32186394
[TBL] [Abstract][Full Text] [Related]
23. Antipsychotics and pituitary tumors: an analysis of the European pharmacovigilance database (EudraVigilance).
Lertxundi U; Erezuma I; Hernandez R; Medrano J; Garcia M; Aguirre C
Int Clin Psychopharmacol; 2019 Mar; 34(2):89-92. PubMed ID: 30531551
[TBL] [Abstract][Full Text] [Related]
24. Ubrogepant and rimegepant: signal detection using spontaneous reports of adverse events from the Food and Drug Administration Adverse Event Reporting System.
Battini V; Carnovale C; Clementi E; Sessa M
Expert Opin Drug Saf; 2023; 22(11):1105-1112. PubMed ID: 37293948
[TBL] [Abstract][Full Text] [Related]
25. Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004).
DuMouchel W; Fram D; Yang X; Mahmoud RA; Grogg AL; Engelhart L; Ramaswamy K
Ann Clin Psychiatry; 2008; 20(1):21-31. PubMed ID: 18297583
[TBL] [Abstract][Full Text] [Related]
26. Are finasteride-related penile curvature/Peyronie's disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases.
Schifano N; Capogrosso P; Boeri L; Fallara G; Chiappini S; Rewhorn M; Cakir OO; Harvey H; Castiglione F; Alnajjar HM; Muneer A; Deho' F; Schifano F; Montorsi F; Salonia A
Int J Impot Res; 2023 Aug; 35(5):465-471. PubMed ID: 35513712
[TBL] [Abstract][Full Text] [Related]
27. A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Patel NM; Stottlemyer BA; Gray MP; Boyce RD; Kane-Gill SL
Cardiovasc Drugs Ther; 2022 Apr; 36(2):309-322. PubMed ID: 33599896
[TBL] [Abstract][Full Text] [Related]
28. Antipsychotics-associated serious adverse events in children: an analysis of the FAERS database.
Kimura G; Kadoyama K; Brown JB; Nakamura T; Miki I; Nisiguchi K; Sakaeda T; Okuno Y
Int J Med Sci; 2015; 12(2):135-40. PubMed ID: 25589889
[TBL] [Abstract][Full Text] [Related]
29. Drug-induced parkinsonism: Revisiting the epidemiology using the WHO pharmacovigilance database.
de Germay S; Montastruc F; Carvajal A; Lapeyre-Mestre M; Montastruc JL
Parkinsonism Relat Disord; 2020 Jan; 70():55-59. PubMed ID: 31865063
[TBL] [Abstract][Full Text] [Related]
30. Post-marketing safety of anti-IL-5 monoclonal antibodies (mAbs): an analysis of the FDA Adverse Event Reporting System (FAERS).
Zou SP; Yang HY; Ouyang M; Cheng Q; Shi X; Sun MH
Expert Opin Drug Saf; 2024 Mar; 23(3):353-362. PubMed ID: 37610085
[TBL] [Abstract][Full Text] [Related]
31. Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems.
Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E
Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1098-1107. PubMed ID: 29174026
[TBL] [Abstract][Full Text] [Related]
32. Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe.
Raschi E; Poluzzi E; Godman B; Koci A; Moretti U; Kalaba M; Bennie M; Barbui C; Wettermark B; Sturkenboom M; De Ponti F
PLoS One; 2013; 8(11):e81208. PubMed ID: 24278396
[TBL] [Abstract][Full Text] [Related]
33. Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system.
Chen JJ; Huo XC; Wang SX; Wang F; Zhao Q
Int J Clin Pharm; 2022 Dec; 44(6):1351-1360. PubMed ID: 36178607
[TBL] [Abstract][Full Text] [Related]
34. A safety signal of somnambulism with the use of antipsychotics and lithium: A pharmacovigilance disproportionality analysis.
Gouverneur A; Ferreira A; Morival C; Pageot C; Tournier M; Pariente A
Br J Clin Pharmacol; 2021 Oct; 87(10):3971-3977. PubMed ID: 33713370
[TBL] [Abstract][Full Text] [Related]
35. The association between receptor binding affinity and metabolic side effect profile of antipsychotics and major cardio- and cerebrovascular events: A case/non-case study using VigiBase.
Aguiar JP; Alves da Costa F; Egberts T; Leufkens H; Souverein P
Eur Neuropsychopharmacol; 2020 Jun; 35():30-38. PubMed ID: 32409260
[TBL] [Abstract][Full Text] [Related]
36. The impact of anti-TNFα agents on weight-related changes: new insights from a real-world pharmacovigilance study using the FDA adverse event reporting system (FAERS) database.
Mazhar F; Battini V; Gringeri M; Pozzi M; Mosini G; Marran AMN; Akram S; van Manen RP; Radice S; Clementi E; Carnovale C
Expert Opin Biol Ther; 2021 Sep; 21(9):1281-1290. PubMed ID: 34191656
[TBL] [Abstract][Full Text] [Related]
37. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
38. Risk excess of mortality and use of antipsychotics: a case-noncase study.
Martín Arias LH; Treceño Lobato C; Pérez García S; Sáinz Gil M; Sanz Fadrique R; García Ortega P
Int Clin Psychopharmacol; 2017 Jan; 32(1):1-5. PubMed ID: 27602888
[TBL] [Abstract][Full Text] [Related]
39. Characteristics of adverse reactions among antipsychotic drugs using the Korean Adverse Event Reporting System database from 2010 to 2019.
Oh S; Byeon SJ; Chung SJ
J Psychopharmacol; 2022 Sep; 36(9):1041-1050. PubMed ID: 35695641
[TBL] [Abstract][Full Text] [Related]
40. Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System.
Raschi E; Mazzarella A; Antonazzo IC; Bendinelli N; Forcesi E; Tuccori M; Moretti U; Poluzzi E; De Ponti F
Target Oncol; 2019 Apr; 14(2):205-221. PubMed ID: 30927173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
